AKEBIA THERAPEUTICS, INC. Debt Securities, Available-for-sale, Allowance for Credit Loss, Period Increase (Decrease)
AKEBIA THERAPEUTICS, INC. (AKBA) reported Debt Securities, Available-for-sale, Allowance for Credit Loss, Period Increase (Decrease) of $0 for the 3-month period ending 2021-09-30, per its 10-Q filed 2021-11-04.
Discontinued › Notes › Credit Losses › Allowance for Credit Loss
us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLossPeriodIncreaseDecrease · last filed 2021-11-04
- AKEBIA THERAPEUTICS, INC. debt securities, available-for-sale, allowance for credit loss, period increase (decrease) for the quarter ending 2021-09-30 was $0.00.
- AKEBIA THERAPEUTICS, INC. debt securities, available-for-sale, allowance for credit loss, period increase (decrease) for the quarter ending 2021-06-30 was $0.00.
- AKEBIA THERAPEUTICS, INC. debt securities, available-for-sale, allowance for credit loss, period increase (decrease) for the quarter ending 2021-03-31 was $0.00.
- AKEBIA THERAPEUTICS, INC. debt securities, available-for-sale, allowance for credit loss, period increase (decrease) for the quarter ending 2020-09-30 was $0.00.
| Period end | Debt Securities, Available-for-sale, Allowance for Credit Loss, Period Increase (Decrease) 3 month | Debt Securities, Available-for-sale, Allowance for Credit Loss, Period Increase (Decrease) 6 month | Debt Securities, Available-for-sale, Allowance for Credit Loss, Period Increase (Decrease) 9 month |
|---|---|---|---|
| 2021-09-30 | $0.00 10-Q · filed 2021-11-04 | $0.00 derived: sum of 2 quarters · filed 2021-11-04 | $0.00 10-Q · filed 2021-11-04 |
| 2021-06-30 | $0.00 10-Q · filed 2021-08-05 | $0.00 10-Q · filed 2021-08-05 | |
| 2021-03-31 | $0.00 10-Q · filed 2021-05-10 | ||
| 2020-09-30 | $0.00 10-Q · filed 2021-11-04 | $0.00 derived: sum of 2 quarters · filed 2021-11-04 | $0.00 10-Q · filed 2021-11-04 |
| 2020-06-30 | $0.00 10-Q · filed 2021-08-05 | $0.00 10-Q · filed 2021-08-05 | |
| 2020-03-31 | $0.00 10-Q · filed 2021-05-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Lyell Immunopharma, Inc. (LYEL) | United States | $0.248B | -1.32 |
| Pyxis Oncology, Inc. (PYXS) | United States | $0.244B | |
| Greenwich LifeSciences, Inc. (GLSI) | United States | $0.267B | -15.02 |
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |
| Cue Biopharma, Inc. (CUE) | United States | $0.243B | -1.01 |
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |
| Mereo BioPharma Group plc (MREO) | $0.269B | -9.41 | |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |